Neutrophilic Dermatoses Flashcards

You may prefer our related Brainscape-certified flashcards:
1
Q

Sweet syndrome 3 subtypes

A

@ Acute febrile neutrophilic dermatoses

Classical

Malignancy associated

Drug induced

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Sweet syndrome associated diseases

A

INFECTIONS (classical)
Upper resp tract infections esp Streptococcal
GI infections i.e. salmonella, Yersinia
Mycobacterial infections

IBD (classical)
Ulcerative colitis
Crohns disease

ENDOCRINE
Pregnancy
Autoimmune thyroid disease

IMMUNOLOGICAL
Lupus erythematosus
Sjogren syndrome
Collagen vascular disorders

OTHER INFLAMMATORY CONDITIONS
*Sarcoidosis
*RA
Still’s disease
SAPHO
OTHER NEUTROPHILIC DERMATOSES —> concurrently or sequentially
PG
Neutrophilic dermatosis of the dorsal hands
Behcet’s disease
Erythema elevatum diutinum
Erythema nodosum
Relapsing polychondritis
Neutrophilic eccrine hidradenitis
Subcorneal pustular dermatoses
Various vasculitis
HAEM MALIGNANCIES (malignancy associated) —> majority have malignancy prior to Sweet syndrome
*AML
*Promyelocytic leukaemia
*CML
*Multiple myeloma
*Myelodysplastic syndrome
Polycythaemia
Aplastic anaemia
Fanconi’s anaemia
Monoclonal gammopathy
Lymphomas (less common)
SOLID ORGAN MALIGNANCIES (malignancy associated) —> majority have Sweet syndrome prior to occurence of malignancy, but malignancy typically Dx within 12 months
Breast
Larynx
GIT
GUT
Prostate
MEDICATIONS (drug induced)
G-CSF
Chemotherapy
Imatinib (KIT inhibitor)
Neutrophil maturation drugs
Retinoids
Antibiotics
Antiepileptics
HAART (highly active antiretroviral therapy)
Anti-HTN
Diuretics
NSAIDS
Contraceptives
Propylthiouracil
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Classical Sweet syndrome clinical features

A

Hx —> any prior hx of fevers or infectious illness

Most have fevers and history of infection

Tender red papules, nodules, plaques
Head, neck, upper trunk, upper arms
Often oedematous —> May become studded with pseudovesicles or pseudopustules (due to the odema)
Subsequently definite vesicles and pustules —> ulceration

Arthralgia

Conjunctivitis, episcleritis

Oral, genital mucosa ulceration uncommon

Systemic (extracutaneous) manifestations

  • Bone
  • Muscle
  • Tendons
  • Neuro-Sweet’s (CNS) —> benign encephalitis, aseptic meningitis, brainstem lesions, psych symptoms
  • Heart
  • lung —> neutrophilic inflammation of bronchi, aseptic pulmonary effusion with abundant neuts (SOB)
  • Liver
  • Intestine
  • Spleen
  • Kidney
  • Subcutaneous (Sweet’s panniculitis)

COURSE
Spontaneous resolution may occur often within 3 months
1/3 untreated cases —> pattern of fluctuating exacerbations and recurrence

COMPLICATIONS
Resolves with no sequelae (majority)
Severe skin lesions with ulceration or delayed Rx —> scarring

UNUSUAL CONSEQUENCES
*Acquired cutis laxa
Mid-dermal elastolysis
Elastophagocytosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Malignancy-associated Sweet syndrome clinical features

A

Hx —> current or previous malignant disease

More widespread distribution

Skin lesions more likely to be

  • Vesicular
  • Bullous
  • Ulcerative

Oral lesions/ulceration

Frequent assoc with

  • Abnormal platelet counts
  • Anaemia

Haem malignancies —> occur before onset Sweet syndrome

Solid tumour malignancies —> Sweet syndrome mostly presented prior to malignancy, but Dx within 12 months of omset of Sweet syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Drug-induced Sweet syndrome clinical features

A

Hx —> new drug administration

2 main types

  • GCSF-associated (more common)
  • Other drugs

Should be a close relationship between drug ingestion and clinical symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

3 Clinical variants

A

Neutrophilic dermatosis of the dorsal hands

Subcutaneous Sweet syndrome

Histiocytoid Sweet syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Neutrophilic dermatosis of the dorsal hands (clinical variant)

A

Identical clinical lesions
Identical histo
Identical demographics
Identical disease associations

Bluish, haemorrhagic papules, bullae, nodules
On the dorsal hands

Typical Sweet syndrome lesions seen at other sites in 50%

Reaponds promptly to

  • prednisolone OR
  • dapsone

DDX
Bullous PG
Pustular vasculitis

ASSOCIATED DISEASES —> may have greater assoc with malignancy
Myeloproloferative disorders
Occult malignancy
IBD
RA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Subcutaneous Sweet syndrome (clinical variant)

A

Erythema nodosum-like
Tender, subepidermal nodules
Extremities, usually legs

Assoc with Haem malignancy —> atypical skin lesions with histology of Sweet syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Histiocytoid Sweet syndrome (clinical variant)

A

HISTO
Infiltrate composed of large histiocytoid mononuclear cells (look like histiocytes)

IHC FOR MYELOPEROXIDASE
Positive —> suggests immature myeloid cells and neut precursors

SKIN LESIONS
May resemble classical Sweet syndrome or with subcutaneous erythema nodosum type lesions

ASSOCIATIONS
Classical/idiopathic subtype
Haem malignancy assoc
Drug induced

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Sweet syndrome Diagnostic criteria

A

MAJOR
Acute onset of typical lesions
Histo findings consistent with Sweets syndrome

MINOR
Fever > 38

Assoc with

  • Malignancy
  • Inflammatory disorder
  • Pregnancy
  • Antecedent respiratory or GI infection

Excellent respinse to systemic CS or potassium iodide

Abnormal lab values at presentation (3 of 4 required)

  • ESR < 20mm
  • Elevated CRP
  • Leukocytes > 8000
  • Neuts > 70%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Sweet syndrome Clinical DDx

A

INFECTIOUS DISORDERS
Erysipelas
Cellulitis
HSV (vesicular)

INFLAMMATORY
Panniculitides
PG
Syphilis
TB

NEOPLASTIC
Mets

REACTIVE ERYTHEMAS
Erythema nodosum (EN)
Erythema multiforme (EM)
Urticarial

SYSTEMIC DISEASE
Behcet disease
Lupus
Bowel bypass syndrome

VASCULITIS
Erythema elevatum diutinum (EED)
Polyarteritis nodosa (PAN)
Granuloma faciale (if on the face)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Sweet syndrome Histo DDx

A

Leukaemia cutis

Leukocytoclastic vasculitis

Neutrophilic eccrine hidradenitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Sweet syndrome Investigations

A

FULL HX

MEDICAL EXAM —> malignancy screen
Lymph nodes
Breasts (women)
Pelvis (women)
Prostate (men)
Testicles (men)

SKIN BX

ROUTINE BLOODS
FBC (leukocytosis, neutrophilia, haem malignancy)
LFT (systemic manifestation)
U/E (systemic manifestation)
CRP (raised)
ESR (raised)
ADDITIONAL BLOODS (as guided by clinical findings)
ASOT (strep infection)
TFT (autoimmune thyroid disease)
Rh factor (RA)

OTHER
Sigmoidoscopy (in age > 50 yrs) —> malignancy screen
Futher Ix to exclude malignancy may be considered if no apparent cause

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Sweet syndrome Pathogenesis

A

External or internal trigger causing alterations in cell signalling and cytokine production
Leads to increase in neut production
Leads to migration into skin and occasionally other tissues

Elevated levels of GCSF

Pathergy (disease triggered at a site following minimal trauma)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Sweet syndrome Histo

A

Prominent dermal oedema
+/- subepidermal vesicles

Dense infiltrate of neuts in the dermis
+/- lymphocytes, eso, histiocytes

Leukocytoclasis
Endothelial swelling without fibrinoid necrosis
Genuine vasculitis not seen

Cell infiltrate Usually diffuse
Perivascular and dermal band patterns seen

Overlying epidermis usually normal
Exocytosis of neuts may be seen
Spread of neuts to subcut fat possible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Sweet syndrome treatment ladder

A

FIRST LINE
Systemic CS prednisolone 0.5-1mg/kg/day for 4-6 weeks
- adjuvant bone protection i.e. Vit D, calcium
- if remission has not been induced after 3 months —> add steroid sparing agent

Potent TCS (mild localised disease)

ILCS (mild localised disease)

SECOND LINE —> no evidence base as to which should be tried first
Dapsone 50-100mg/day
- close monitoring of FBC for haemolysis
- cautious approach with 50mg taking time to be effective but not triggering haemolysis
- haem S/E frequent with 100mg or more

Potassium iodide 300mg TDS

Colchicine 0.5mg TDS
- GI S/Es dose related i.e. nausea, diarrhoea, vomiting

THIRD LINE
Ciclosporin
Clofazimine
IVIg

Indomethacin (NSAID)
Cyclophosphamide (cytotoxic)
Chlorambucil (cytotoxic)
Anti-TNF
Thalidomide (beware child bearing F)
Interferon-alpha
17
Q

Pyoderma gangrenosum subtypes

A

Classical ulcerative form

Parastomal

Pustular

Bullous (Atypical)

Granulomatous superficial

Neutrophilic dermatosis of the dorsal hands (see under sweet syndrome variant)

Extracutaneous PG

18
Q

Classical PG Diagnostic criteria

A

MAJOR CRITERIA
Rapid progression

of a painful necrolytic skin ulcer

with an irregular violaceous and undermined border

Exclusion of other causes of cutaneous ulceration

MINOR CRITERIA (2 should be met)
A hx suggestive of pathergy, or the clinical finding of cribroform scarring

Systemic disease known to be assoc with PG

Histopathological findings

  • Sterile dermal neutrophilia +/- mixed inflammation +
  • Lymphocytic vasculitis (leukocytoclasia, endothelial swelling, no fibrinoid necrosis)

Rx response
- Rapid response to systemic CS

19
Q

PG associated diseases

A

IBD (especially in the pustular variant of PG)

  • Crohn disease
  • Ulcerative colitis

RA

Other seronegative arthritis

Haem malignancy (especially in the bullous form of PG)
Monoclonal gammopathy

Other visceral malignancies

DISEASE ENTITIES WITH PG
PAPA syndrome
- Pyogenic arthritis
- PG
- Acne

PASH syndrome (lacks genetic abnormalities and arthritis of PAPA syndrome)

  • PG
  • Cystic Acne
  • Hidradenitis
PG CO-MORBIDITIES (either predispose to PG or a result from PG)
Diabetes (long term pred)
Peripheral vascular disease
Obesity
Depression
Anaemia
Renal impairment
Thyroid disease
20
Q

PG predisposing factors

A

Pathergy (skin trauma provokes lesions, or first onset of dosease is at the site of injury)

  • following surgical wound
  • following penetrating injury

In ulcerative colitis patients with PG

  • Smoking
  • Appendicectomy
21
Q

PG pathogenesis

A
MULTIFACTORIAL
Prediposition to inflammatory cascade, including
- Activation of innate immunity
- Autoinflammtory pathways
- Cytokines

If drug-induced esp thiouracils —> may be C-ANCA or P-ANCA positive

GENETICS
PAPA syndrome —> PSTPIP1/CD2BP1 mutation

22
Q

Classic ulcerative PG (PG subtype)

A

Commonest, best recognised variant

Small tender red blue papules, plaques, pustules

Evolve into painful ulcers

Characteristic violaceous undermined edge

Ulcer base —> there may be granulation tissue, necrosis, purulent exudate

Solitary or multiple ulcers

Most commonly on the legs, may affect any body site i.e. genitals, mucosae

Healing —> occurs with an atrophic cribriform scar

Associated symptoms

  • Fever
  • Malaise
  • Myalgia
  • Arthralgia
23
Q

Parastomal PG (PG subtype)

A

May arise as pathergy response to

  • Trauma of appliances
  • Faecal irritation

Most common with ileostomy for active IBD

Risk factors

  • Higher BMI
  • F
  • Autoimmune disorders
24
Q

Pustular PG (PG subtype)

A

Assoc with IBD —> Often occurs during acute exacerbations of IBD

Discrete painful pustules with surrounding halo of erythema develop on normal skin

Commonly arise scattered on the extensor aspects of the limbs

DDX OF OTHER PAINFUL PUSTULAR ERUPTIONS IN THE CONTEXT OF IBD
BADAS (Bowel-associated dermatitis-arthritis syndrome)
Subcorneal pustular dermatosis
Pyostomatitis vegetans (predominanly mucosal pustules)

25
Q

Bullous PG (Atypical PG, PG subtype)

A

Assoc with myeloproliferative disorders

Rapidly arising
Superficial haemorrhagic bullae
Often located on the arms

Shares clinical and histological findings with Sweet syndrome but
Typically ulcerates
Heals with scarring

ASSOCIATED DISEASES
Myeloproliferative disorders —> PG can precede the onset of malignancy —> should be investigated with high index of suspicion for haem malignancy

26
Q

Granulomatous superficial PG (vegetative PG, PG subtype)

A

Superficial lesions of PG

With a granulomatous histology

Begins with single superficial ulcer with granulations and elevated edge

Most often on trunk

Lower incidence of associated conditions (idiopathic)

More responsive to Rx than other variants

  • TCS
  • ILCS
  • systemic CS
  • minocycline
  • Dapsone
27
Q

Extracutaneous PG (PG subtype)

A

Aseptic abscessus

Lungs (most common)
Bones
Liver
Heart
Brain
GIT
Muscle
28
Q

Non-classical PG DDx

A

Vascular occlusive or venous disease

Vasculitis

Malignancy

Primary infection —> Bx and tissue culture

  • Fungi
  • atypical mycobacteria
  • Sporotrichosis
  • Mucormycosis
  • Histoplasmosis
  • Blastomycosis

Drug-induced
- Nicorandil

Exogenous tissue injury

29
Q

PG Complications

A

Mortality ? from secondary infection, immunosuppressive Rx, or combo

PG COMPLICATIONS/CO-MORBIDITIES (either predispose to PG or a result from PG)
Diabetes (long term pred)
Peripheral vascular disease
Obesity
Depression
Anaemia
Renal impairment
Thyroid disease
30
Q

PG course and prognosis

A

Chronic condition

Takes many months or years to completely resolve

May be recurrent —> consider long term systemic preventive Rx

31
Q

PG investigations

A

EXAM
Lymphadenopathy (malignancy)

SKIN BX
Not diagnostic, but performed in all (except classical Ulcerative PG) to exclude other conditions that may minic PG particularly infection
Bx for H&E, and
Bx for tissue culture (bacterial, mycobacterial, fungal, viral)

BLOODS
FBC (haem malignancy)
ELFT
Blood culture (infection)

IMAGING
CXR (TB, malignancy)
CT scan (malignancy)

OTHER
Endoscopy (IBD, malignancy)
BMAT (malignancy)

32
Q

PG histology

A

No typical histology

Skin bx taken to exclude other causes of ulceration esp infection that mimic PG clinically

Neutrophilic pustules (early lesions)

Features generally non-specific

Presence of vasculitis debatable —> may be secondary to ulceration

If vasculitis is present —> exclude vasculitides and infective causes —> tissue culture, special stains of tissue for fungi, mycobcteria

TYPICAL FINDINGS
Central necrosis
Ulceration of the epidermis + dermis
Surrounded by intense mixed to chronic inflammatory cell infiltrate

CLASSIC ULCERATIVE SUBTYPE
Massive dermal epidermal neutrophilic infiltrate with suppurative/abscess formation

PUSTULAR SUBTYPE
Perifollicular neutrophilic infiltrate with subcorneal pustule formation

BULLOUS SUBTYPE
Neutrophilic infiltrate with intraepidermal vesicle formation

SUPERFICIAL GRANULOMATOUS (VEGETATIVE) SUBTYPE
Granulomatous reaction with peripheral palisading histiocytes and giant cells
33
Q

PG management

A

FIRST LINE
Analgesia

Supportive Rx to promote wound healing

  • Dressings
  • Topicals for cleansing and debriding and keeping wound moist
  • Compression

Potent TCS (small lesions)

ILCS (small lesions)

Topical tacrolimus ointment (small lesions)

SECOND LINE (more severe dosease, or PG not responding to simple measures)

  • Systemic CS (mainstay Rx)
  • Oral prednisolone 0.5 - 1mg/kg/day
  • CSA 5mg/kg
  • Combined oral prednisolone + CSA

Pulsed oral prednisolone 1mg/kg/day for 5 days

MTX

MMF

Dapsone

Others

  • Tetracyclines
  • Thalidomide
  • Tacrolimus
  • Cyclophosphamide
  • Chlorambucil
  • AZA
  • Colchicine

THIRD LINE mainly d/t cost (Biological Rx)
Anti-TNF (should be comsidered more often as 1st line esp those with IBD)
- Infliximab**
- Adalimumab —> risk of paradoxical onset of PG
- Etanercept —> risk of paradoxical onset of PG

IL12/23
- Ustekinumab

Anti- IL1
- Anakinra (successful for PAPA, PASH syndrome)

IVIg

Topical platelet derived growth factor

ALTERNATIVE RX
Skin graft (although surgery should be avoided in the inflammatory stage and can grequently induce PG, skin graft can be successful if inflammation has already resolved following systemic Rx with oral CS)

Granulocyte apheresis

Topical sodium cromoglycate

Topical nicotine

Hyperbaric oxygen

34
Q

BADAS (Bowel-associated dermatitis-arthritis syndrome)

A

DEFINITION
Pustular vasculitic lesions

Assoc with blind loops of bowel

Or other causes of stasis of bowel content

CLINICAL FEATURES
Begins as small macular lesions
Progress into papules —> pustules on an erythematous purpuric base
Arms, other areas on upper body

Pustules typically occur in crops
Each crop lasts ~ 2 weeks

Recurring at intervals of several months

Other lesion types

  • larger erythema nodosum-like lesions
  • larger PG-like pustular lesions

Pathergy

Lesions May be preceded by constitutional symptoms -

  • Fever
  • Flu-like symptoms
  • Myalgia
  • GIT upset

Arthralgia or non-erosive polyarthritis —> acute inflammatory with tenderness, swelling

  • Hands
  • Wrists
  • Other peripheral joints

Ocular
- Episcleritis

GUT

  • Haematuria
  • Proteinuria
DDX
Behcet disease (oral aphthae, lesions of pustular vasculitis)

PATHOGENESIS
Proliferation of bowel flora antigen (peptidoglycans) —> circulating immune complexes —> immune complex-mediated blood vessel damage

PREDISPOSING FACTORS causing blind loops of bowel or stasis of bowel contents
Jejuno-ileal bypass surgery
Gastric resection
Blind loops of bowel
Defunctioning ileo-anal pouch
Bilio-pancreatic diversion

IBD

  • Crohn disease
  • Ulcerative colitis

Diverticulitis of the colon

Jejunal diverticula

Appendicitis

Achalasia of the gastric cardia

Combined causes i.e. surgery for IBD

DX
Requires clinicopathologic correlation

IX
Swab MCS of pustules
Urinalysis (haematuria, proteinuria —> immune complex initiated glomerulonephritis)

HISTO
Pustular vasculitis —> similar to Sweet syndrome

MX
Surgical correction of bowel anatomy (for patients following bowel bypass surgery) —> often eliminates signs and symptoms
Surgical correction difficult for patients with blind loops of bowel —> resolution of sumptoms less likely

SYSTEMIC RX (first line —> antibacterials —> suggests role of bacterial colonisation in trigerring systemic response in BADAS)
Oral tetracycline
Oral metronidazole
Oral ciprofloxacin
Oral erythromycin

SYSTEMIC RX (second line) —> may need to be combined with appropriate AB
Oral prednisolone
- usually unnecessary
- but may be justified depending on degree of skin, joint, systemic symptoms, or manage IBD)

Oral colchicine

Oral dapsone

Oral MMF

35
Q

Subcorneal pustular dermatosis @ Sneddon-Wilkinson disease

A

DEFINITION
Sterile subcorneal pustules
Affecting flexural areas of trunk and proximal extremities

CLINICAL FEATURES
Sterile oval pea-sized pustules on a normal or erythematous base

May see characteristic fluid level

  • Pus lower half
  • Clear fluid upper half

Pustules may be isolated or grouped, coalescing to form annular or serpiginous patterns

Successive waves may pass ofer the same area

Pustules may rupture in the flexures —> becomes indistinct

Acute flares lasts several days or weeks

Flexures of the trunk, proximal limbs (axillae, groin, submammary, neck, apron)
Spares face, mucous membrane

ASSOCIATED DISEASES
Benign monoclonal gammopathy (more commonly IgA)
Multiple myeloma
Lymphomas
IBD
PG
RA
Connective tissue disease incl. SLE
PATHOGENESIS
Obscure
Linked to 
- excessive production of TNF-alpha
- Neutrophil activation
—> in common with other neutrophilic dermatosis

? Overlap with pemphigus (but most cases DIF megative)
—> a subset has IgA deposited in the upper dermis directed against desmocollin 1 —> IgA pemphigus —> relationship between IgA pemphigus and classic subcorneal pustular dermatosis unclear

DDX
Impetigo
Pustular psoriasis (spongiform pustules, unlike subcorneal pustular dermatosis)
AGEP (fevers, recent drug exposure)
Pemphigus foliaceus
IgA Pemphigus (DIF intercellular IgA)
Dermatitis herpetiformis (this is usually on extensor surfaces, rather than flexures)

IX
Skin swab MCS (exclude impetigo)
Skin biopsy of early pustules (most recent pustules)
Skin bx of perilesional skin for DIF (DDx IgA pemphigus)
Anti-skin antibodies (Pemphigus)
FBC + diff, SPEP, UPEP + immunofixation, serum free light chains (Exclude multiple myeloma)
Rh factor, anti-CCP (Exclude RA) —> only if indicated by hx
ANA (exclude autoimmunity) —> only if indicated by hx
Faecal calprotectin (exclude IBD) —> only if indicated by hx

HISTO
Perivascular inflammatory infiltrate with occasional EOSINOPHILS
Pustules sit on the surface of the viable epidermois
No spongiosis
No spongiotic pustules
IHC neg (positive in intercellular IgA pemphigus)

MX
Rx underlying associated disease
Rx condition

FIRST LINE RX
Dapsone 50-150mg daily —> partial or complete response

SECOND LINE RX
Potent TCS —> not really effective
Oral CS —> not really effective
Acitretin
Tacalcitol
NbUVB
PUVA
Oral retinoids + PUVA
CSA + oral pred

THIRD LINE RX
Oral ketoconazole
Anti-TNF (case reports)
- Etanercept
- Adalimumab (combined with other immunosuppressant i.e. MMF)
- Infliximab (combined with other immunosuppressants i.e. pred, AZA)

COURSE/PROGNOSIS
Benign but chronic

36
Q

Pyodermatitis-Pyostomatitis vegetans @ Pyoderma vegetans

A

Some consider this the oral mucosal form of pustular PG

CLINICAL FEATURES
Oral mucosal thickening with multiple pustules, Snail track superficial ulceration on an erythematous base
Any site of oral mucosa
But tongue less affected

Skin lesions may be present

  • often flexural
  • Clinically suggestive of pemphigus vegetans with verrucous plaques studded with pustules
  • may be assoc dorsal hand lesions morphologically similar to neutrophilic dermatosis and rash resembling Sweet syndrome
  • May display pathergy
ASSOCIATED DISEASES
IBD esp ulcerative colitis (strongest assoc)
Leukaemias
Lymphomas
Follicular occlusion syndromes
- Acne conglobata
- HS
- Dissecting cellulitis
Immunosuppression
Malnutrition

PATHOGENESIS
Unknown
Suggested immunological and microbial factors
May represent abnormal response to infection (various bcteria reported as causative)

IX
Total IgE (raised)
FBC (peripheral eosinophilia)

HISTO ORAL MUCOSAL LESIONS
Intraepithelial and/or subepithelial abscesses containing large numbers of EOSINOPHILS
Deeper tissue have mixed infiltrate of neuts, eos
Often assoc peripheral blood EOSINOPHILIA

HISTO SKIN LESIONS (IF PRESENT) —> verrucous plaques studded with pustules
Pseudoepitheliomatous hyperplasia
Neutrophilic abscesses
Negative DIF
—> unlike pemphigus vegetans

MX
Antimicrobials (if cause uncertain)

RX FOR ORAL DISEASE
First line
- TCS
- TCI (tacrolimus)
- Oral pred when topicals fail

Second line

  • Dapsone
  • Oral pred +/- AZA
  • CSA
  • Adalimumab
  • MTX + infliximab (Crohn assoc cases)
37
Q

Amicrobial pustulosis of the skin folds

A

Most cases occur in patients with SLE

CLINICAL FEATURES
Rapidly evolving small semi-confluent pustules
Pustules —> erosions, crusts
Predominatly affect flexures —> 1 major (axilla, inguinal) + 1 minor skin fold (face, scalp) affected
Alopecia if affects scalp

ASSOCIATED DISEASES (mainly autoimmune conditions)
SLE (most cases)
Coeliac disease
Autoimmune thyroid disease
Autoimmune hepatic disease
Crohn disease
Sjogren disease
IgA nephropathy

DIAGNOSTIC CRITERIA
Major criteria
- Pustulosis involving 1 or more major skin fold
- Pustulosis involving 1mor more minor skin folds in the anogenital area
- Histo pattern with intraepidermal spongiform pustules + mainly neutrophilic dermal infiltrate
- Negative culture from unopened non-ruptured pustule

Minor criteria

  • Assoc with 1or more autoimmune disorders
  • Positive ANA 1:160 or higher
  • Autoantibodies ENA, anti-dsDNA, anti-smooth muscle, anti-mitochondrial, antiendomesial

DDX
Subcorneal pustular dermatosis
Pustular psoriasis
Erosive pustular dermatosis of the scalp (if involves scalp)

IX
Neutrophilic epidermal and ostial exocytosis
Spongiform pustules
Neutrophilic dermal infiltrate
Variable DIF positivity for IgM, C3, IgG (endothelium or lupus band)

FIRST LINE RX
Oral pred

SECOND LINE RX
Dapsone
CSA
Oral zinc
TCS
Colchicine
Cimetidine
Ascorbic acid
Anakinra (if IL-1 demonstrated to be involved)